MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley +1 more source
Extracellular vesicles in nipple discharge for breast cancer screening. [PDF]
Ozaki Y +16 more
europepmc +1 more source
Rare Secondary Neoplasms Arising in Epidermal Nevus: A Case Series and Literature Review
ABSTRACT Malignant transformation is known to occur with many nevi, such as nevus sebaceus. However, cases of secondary tumors developing in an epidermal nevus (EN) are rare, with only a few case reports documented in the literature. We present three unique cases of syringocystadenoma papilliferum (SCAP), syringofibroadenoma, trichilemmoma, and basal ...
Haya A. Homsi +5 more
wiley +1 more source
Synchronous Lobular Breast Cancer and Lung Adenocarcinoma: Α Case Report. [PDF]
Pantelidou V +5 more
europepmc +1 more source
Gigantic invasive ductal carcinoma of the breast
Andrea P. Damin +4 more
openaire +2 more sources
ABSTRACT Endocrine mucin‐producing sweat gland carcinoma (EMPSGC) is an adnexal neoplasm which typically occurs on periorbital skin and demonstrates overlapping histopathologic features with primary mucinous carcinoma of the skin (MCS). Herein, we report a patient who developed five distinct lesions of EMPSGC and MCS over an eight‐year period, some of ...
Ikuko Hirai +5 more
wiley +1 more source
Case Report: A rare triad of neoplasms: navigating synchronous accessory breast cancer, papillary thyroid carcinoma, and inflammatory nasal papilloma. [PDF]
Zeng X +9 more
europepmc +1 more source
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Case Report: response of HER2-positive ductal carcinoma <i>in situ</i> to osimertinib with supporting <i>in vitro</i> evidence. [PDF]
Baba S +7 more
europepmc +1 more source
Digital exercise interventions to improve physical functioning of people with breast cancer: Protocol for a scoping review. [PDF]
Mankelow KA +4 more
europepmc +1 more source

